Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Axe are you having some kind of nervous breakdown?
You have gone all ******ed in your last few posts. Might be best if you take a break from this stressful world of investing. Seek medical assistance buddy.
Dungk! Very grown post! I will bring a Highchair to the SNG Party for you. :)
It's obvious from the writing style who is running the sockpuppets. Their writing is unhinged.
Check out ADVFN forum, there is a poster on there addressing people on this site.
We know who the sockpuppets are: green bin them. Their insanity wants attention. Don't feed it.
Axe have you been drinking all day?
As any sensible and competent investor would Donk whilst in this period! Sorry Dink! Ooops Doink! Bu**er D**K! Dunk That's it!
Dare I mention 15 trading days left in August… or is that below the belt.
Looks like another pointless day on the board with the usual suspects bickering with obvious trolls. You make it too easy for them.
As much as Andyb & Mr Costs get called for on here, the share price is currently in the gutter. We can't even hold 30p.
Yet ramp it up and suggest £3 a share then everyone hangs out the back of you.
The sooner we get taken over the better, put us all out of our misery then.
I did say earlier they wanted to get back in the teens... SOoooo predictable..!!
I'll send Paddy my Prize winning carrier Pigeon round to have a liitle chat with them..
He's very persuasive when he's hungry.....!
WARNING to anyone reading this post from Andy.
He is a self confessed trader who has admitted he posts to troll members and have fun.
He also has at least 5 different profiles. His other main profile NDN was eventually banned after he was found out.
Ignore his comments as he is here to push the price down so he can buy in before good news drops
For those new to Synairgen, we ask the question, is it a good investment?
The company itself was able to capitalise from the pandemic with its inhaled interferon treatment against covid. Initially targeting COPD and other respiratory illnesses however failed to be bought out by Astra Zeneca when COPD trial results were inconclusive.
The company then had a great chance at releasing their interferon inhaled treatment during the pandemic. After a successful phase 2 trial the share price rose by 500%. Synairgen found itself amongst the cutting edge of potential therapeutics for Covid19, it was included on the ACTIV trials started with operation warp speed to find new therapeutics designed to treat Covid 19.
The company itself made a fund raise and gained £80 million which was to fund it phase 3 trial. 16 months after the fund raise, the results of their phase 3 trial were released. Unfortunately the phase 3 trial was exceptionally poorly planned and left the share price 85% down, where it remains today.
The CEO of the company insists that he and the team are desperately scrambling to get their drug included on platform trials run by governments, however it has now been six whole months since the disastrous trial result and as of yet there is no news on any new trial.
Covid19 has mutated in to a less harmful virus, however persists to be a problem and could flare up badly during the winter months.
So is there potential with the company?
Like all investments, it’s a gamble. But with Synairgen, as they currently have no product for sale, they do not make any profits. They have a strong enough cash runway to last 24 months, however not enough to fund another trial. The company has said it is desperately looking for new trials to join, however the need to develop new covid therapeutics has decreased due to the giant pharma companies already releasing their drugs which are now available for governments to purchase. Unless they are able to join a government sponsored trial, they will need to do a fund raise for themselves, in which case the shares will be diluted further and the share price will fall accordingly.
Unfortunately the comms from this team is terrible. Many investors who were hopeful of a successful phase 3 outcome were in dismay by the lack of haste or communication by Synairgen to their shareholders.
Due to the diminished need to create new drugs to combat Covid19 and also the increasing likelihood of not getting on to a free sponsored trial it looks like Synairgen are going to be in the wilderness for quite some time. Consensus appears that the current cash runway will be depleted and the need for Covid19 drugs is not great enough to finance heavily sponsored government trials.
The consensus therefore should be to avoid this company, or wait until the share price falls to below 15p and then make an investment as a speculative future gamble.
There are other small upcoming biotech companies that are more worthy